Actelion Archives

multiple sclerosis novartis roche ema approval

News and Trends 27 Apr 2021

EMA Approvals for Multiple Sclerosis Highlight Treatment Shortfalls

While the EU saw rapid-fire approvals in the multiple sclerosis space last month, the innovations centered mostly on improving existing approaches. Which areas of multiple sclerosis treatment need more options?…

April 27, 2021 - 6 minutesmins - By Jonathan Smith

In Depth 23 Dec 2020

Humble Beginnings: The Origin Story of Modern Biotechnology

The history of modern biotechnology began around four decades ago with the invention of genetic engineering. Genentech, one of the fundamental companies in this field, set many trends for modern…

December 23, 2020 - 4 minutesmins - By Jonathan Smith

Best in Biotech 21 May 2019

The Top 20 Women in Leading Biotech Roles in Europe

The biotech industry has often been criticized for its lack of gender diversity. While there is still a long way to go to achieve ideal levels of equality, there are…

May 21, 2019 - 12 minutesmins - By Jonathan Smith

Best in Biotech 2 Apr 2019

The 8 Best Biotech Companies in Europe’s History

We’ve put together a list of the best biotech companies in Europe to celebrate their invaluable contributions to science and the development of the booming industry that biotech is today.…

April 2, 2019 - 8 minutesmins - By Clara Rodríguez Fernández

More News! 18 Jun 2018

Swiss Biotech Tackles Brain Artery Constriction Caused by Hemorrhage

Idorsia will start a Phase III trial to study the efficacy of its drug in treating the constriction of arteries in the brain caused by release of chemicals linked to…

June 18, 2018 - 2 minutesmins - By Alexander Burik

Idorsia Actelion Spin Off Jean Paul Clozel CEO

News and Trends 1 Mar 2018

How is Actelion Spin-Off Idorsia Doing One Year Later?

Actelion's spin-off Idorsia was blessed with a large pipeline and a healthy bank balance. How has the biotech’s first year of business gone? Just over a year ago, Actelion, the…

March 1, 2018 - 3 minutesmins - By Clara Rodríguez Fernández

In Depth 23 Jan 2018

Walking with the Dinosaurs of European Biotech: Which of Them is Roaring the Loudest?

Although biotech may seem like an industry that has only just gotten started, it was already up and running before the turn of the century. We took a look back…

January 23, 2018 - 10 minutesmins - By Alex Dale

News and Trends 20 Dec 2017

Actelion Spin Out and Roche Join Forces to Develop Cancer Immunotherapies

Idorsia and Roche have agreed on a research collaboration, with the big pharma getting exclusive rights to develop and license resultant cancer immunotherapy drugs. Idorsia was formed out of J&J's…

December 20, 2017 - 2 minutesmins - By Alex Dale

Best in Biotech 12 Dec 2017

Grab the Tissues: Here are the 8 Biggest European Biotech Clinical Failures of 2017

As 2016 was a tough year for biotech, 2017 was under pressure to turn things around. Although there has been an improvement, there were some notable speed bumps for the…

December 12, 2017 - 7 minutesmins - By Alex Dale

Best in Biotech 5 Dec 2017

Europe’s Brightest Stars: The 9 Best Biotech Companies of 2017

Tis the season for Glühwein, Tannenbäume, and lights in Berlin, and Labiotech is celebrating with its year-end lists of the top things that happened this year. First up, the best…

December 5, 2017 - 6 minutesmins - By Evelyn Warner

hypertension treatment idorsia janssen2 1

News and Trends 4 Dec 2017

Swiss Biotech Brings in Reinforcements to See Hypertension Drug Through Phase III

Idorsia will collaborate with Janssen on the development of its hypertension drug, aprocitentan, which could help to prevent future heart attacks and strokes. Idorsia was born out of Actelion's massive…

December 4, 2017 - 3 minutesmins - By Alex Dale

In Depth 25 Apr 2017

How Biotech is Mastering Multiple Sclerosis: A Review

With last month’s FDA approval, Ocrevus (ocrelizumab), became the first drug for primary-progressive multiple sclerosis. Roche may be the first, but others in the biotech community are also working hard…

April 25, 2017 - 7 minutesmins - By Diana Kwon

Best in Biotech 18 Apr 2017

The Top 12 Biotech Leaders You Should Know in Basel

After exploring Munich and the Golden Triangle, we head to another biotech hotspot full of people that should be on your list of who's who. Basel is home to some really…

April 18, 2017 - 6 minutesmins - By Denise Neves Gameiro

Best in Biotech 15 Mar 2017

What are the Best Countries to Recruit Biotech Talents in 2017?

Before the “who to recruit” phase, an important question is “where?” We ran through the top countries in which to look for talent in biotech and had a look at what…

March 15, 2017 - 10 minutesmins - By External Contributor

Infographics 21 Feb 2017

Infographic: The Biggest Biotech Company in Each European Country

We had a look into European biotech and created a map with the biggest biotech companies in each country, according to their market cap. Biotech is one of the biggest…

February 21, 2017 - 2 minutesmins - By Clara Rodríguez Fernández

News and Trends 15 Feb 2017

Actelion’s key Drug linked to Deaths, prompting EMA Investigation

Johnson & Johnson is certainly counting on its recent acquisition of the European biotech success Actelion to upgrade its top line. Now Actelion's key product, Uptravi, may be facing some safety issues. One…

February 15, 2017 - 3 minutesmins - By Melanie De Almeida

News and Trends 26 Jan 2017

Europe’s Largest Biotech Actelion Seals the Deal with J&J for €28B

Actelion will be acquired by J&J for a whopping €27.9B, and its early R&D pipeline will be spun out into a new Switzerland-based outfit. The wait is over folks: Actelion, the largest…

January 26, 2017 - 2 minutesmins - By Evelyn Warner

News and Trends 23 Jan 2017

A Placebo beats the Largest European Biotech in Phase III

Actelion's lead drug Opsumit has missed its primary endpoint in Phase III. What are the consequences for the biggest independent biotech in Europe? Actelion is a leader in treatments for pulmonary arterial…

January 23, 2017 - 2 minutesmins - By Clara Rodríguez Fernández

News and Trends 13 Jan 2017

UPDATE: J&J and Actelion settle on a price, R&D assets will be spun out

UPDATE (12/01/2017): J&J and Actelion have reportedly settled on a price: $260 (€245) per share, totaling more than $28 (€26) billion. The Swiss biotech's R&D assets will be spun out…

January 13, 2017 - 4 minutesmins - By Clara Rodríguez Fernández

In Depth 5 Jan 2017

What to Expect from European Biotech Finance in 2017

The new year comes with uncertainty over the future of the biotech industry, whose finance suffered during 2016. What are the expert predictions for 2017? Last year was the worst…

January 5, 2017 - 3 minutesmins - By Clara Rodríguez Fernández

Report: new Frontiers in Vaccinology

Listen to our podcast

View all sectors A-Z

Register for the Webinar

View all companies A-Z

Find new scientific partnerships. Create a free IN-PART account

View all countries A-Z

Report: The European Biotech Startup Ecosystem

Subcribe to our newsletter

Learn more about Inova, the leading platform for biopharma partnering